Medpage Today on MSN6d
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPCAdding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Medpage Today on MSN5d
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPCShe noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ESSA Pharma Inc. (NASDAQ:EPIX) between December 12, 2023 and October 31, 2024, inclusive (the "Class Period"), of ...
Adding talazoparib to first-line treatment with enzalutamide can improve overall survival in patients with mCRPC, phase 3 data suggest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback